Multicenter, open-label, single-arm, fixed dose study of darbepoetin alfa in subjects with
Chronic Renal Insufficiency (CRI). Subjects will be screened for 2 weeks during which time
blood will be drawn and vital signs will be taken. Upon enrollment, subjects will receive SC
darbepoetin alfa administered once every other week for 24 weeks. Darbepoetin alfa will be
titrated in fixed-dose steps to maintain a hemoglobin of 11.0 - 13.0. During the study,
laboratory assessments will be completed and vital signs will be taken. Subjects will enter a
1-week post-treatment observation and evaluation period after the last dose of study drug.